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Abstract: Expression of the target gene is important for gene therapy. Presently, localized transgenesis is 
used for gene therapy which can be achieved by a target gene expression. Here, we have reported the 
plasmid mediated gene therapy to zebrafish model. For  this purpose, we have chosen  green fluorescent 
protein (GFP) as a target gene because the expression can be detected easily.  GFP was inserted in a 
plasmid vector, pQE30 to develop the vector pQE30GFP.  The plasmid pQE30GFP was constructed form 
plasmid, pQE30 and pEGFPC2. pQE30GFP injected directly in one group of fish into the muscle where 
luciferase expression was noted. In another group, after injection electroporation was performed where we 
have also noted luciferase expression; but, electroporation  cause  muscle injury to the zebrafish. In our 
case, the expression was very strong at the site of injection in first group in compare to electroporation 
group and in both the cases expression was stable more than two weeks.
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INTRODUCTION 
Advancements and achievements in gene therapy continue to have a significant importance on gene 
medicine since 1995.  Presently, the potential  for new therapeutics is  unlimited and there have been a 
number of tremendous technological up gradation that have allowed for clinical trials of gene therapy [1] . 
*Both have same contribution
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In recent years, in vivo gene delivery by direct injection is a convenient method to express proteins 
into  skeletal  or  cardiac  muscle  [2,3]  . Over  viral  and other  delivery  systems, plasmid-mediated  gene 
delivery offers several advantages and it has also shown very good promise in preclinical studies [4]. The 
plasmid has the ability to accommodate large  genes. However, skeletal muscle appears to be extremely 
capable to take up and express plasmids in contrast to other tissues. Direct injection of naked DNA leads to 
patchy expression of delivered  genes  among fibers  in  a  given muscle,  which is  a  disadvantage [4,5]. 
Furthermore, plasmid-mediated gene therapy will become a feasible approach for humans along with viral 
vectors, when systemic delivery is achieved. The major hurdles for  plasmid-mediated  gene therapy are 
active exploration [6,7]. However, some degrees of studies in zebrafish gene therapy are currently under 
way [8].
Due to their transparent embryos and rapid organogenesis, zebrafish were established as a tool for 
academic  developmental  biologists  till  date.  Zebrafish  was  used  as  first  vertebrate  large  for  scale 
mutagenesis screen in the 1990s that produced several of mutations, some of which was used as model for 
human diseases. Currently, similar to the mouse, zebrafish has proven to be a useful vertebrate for research 
[9].  Embryogenesis is rapid and large numbers of embryos are generated due to the high fecundity of 
zebrafish. Under ideal conditions, the females spawn up to 300 eggs per week. The eggs also hatch rapidly. 
Eggs and larvae are transparent; early stages of development make zebrafish a suitable model organism to 
study  vertebrate  development  [10,11]  .  To understand  the  gene  function  and  its  expression  in  cells, 
transgenic zebrafish have been consistently produced [12].  Large-scale transgenic zebrafish generation 
method was developed by Powers et al.
 
[13].  Electroporation method was successfully established on 
different fish species eggs [14]. To investigate gene regulation in later stages of zebrafish development, 
electroporation was demonstrated where DNA delivery was done into the neural tube of the embryo[15]. 
Recently, expression methods  of  transgenes in adult fish  have also  investigated. Particle bombardment 
using gene gun, muscular injections of naked DNA and electroporation have been reported [16, 17] . 
The green fluorescent protein (GFP) has a major impact on many areas of sciences, especially on cell 
biology and molecular biology. GFP can be detected in living cells without selection or staining which is 
the greatest advantage of GFP [18]. The potentiality of GFP has also been documented by gene therapy 
researchers through which one can determine the expression level, site and time course of the therapeutic 
gene, or the correlation between gene transfer rate and therapeutic outcome [19, 20]. 
We have explored the possibility of gene transfer using GFP to the level of plasmid-mediated gene 
expression by injection method in skeletal muscle in zebrafish. For that, we have constructed pQE30GFP 
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and have injected this plasmid into the muscle to develop localize transgenic zebrafish (>5 months old). 
These results have significant implications for the blueprint of plasmid-mediated gene therapy by injection 
method into skeletal or cardiac muscle.
MATERIALS AND METHODS
Zebrafish
Adult zebra fish, purchased from a local aqua shop, was maintained as per the guiding principle given 
in  the  zebrafish  book  [21]. The  fish  used  in  these  experiments  were  about  4-6  months  old  and 
approximately 3 cm in length which were kept in 5-10 lit glass aquariums. The aquaria had a continuous 
re-circulating system, consisting of biological filters. Additional oxygen was provided by placing air-stones 
in  the water  and 1/3 of  water  was replaced weekly. Aquariums water  temperature  was maintained at 
28.5°C-32°C and a constant 14/10-h light/dark cycle.
Plasmids
The vector, plasmid pQE30GFP was constructed from two original plasmids pQE30 and pEGFPC2. 
We have digested pEGFP-C2 with the HindIII and KpnI  to isolate enhance-GFP (EGFP). Then we have 
digested pQE30  with
 HindIII  and  KpnI  and  inserted  EGFP  to  obtain  pQE30GFP.  Details  of  the 
construction of plasmids and the composition of pQE30GFP are included in the Fig.1 (A and B).
Intramuscular Injections of GFP Plasmid 
All zebrafish were injected at the age of 4-6 months old.  BD ultra-fine II insulin syringe (1-2 cc 
capacity) was used for injection (Becton Dickinson). The volume of injection was maintained constant at 
10 µl, and the amount of plasmid DNA was 10 µg per construct. The fishes were taken out of the water and 
provided  anesthesia  with  MS-222  for  5-10  minutes  and  then  an  intra-muscular  injection  was  given 
approximately in the end region of the dorsal fin on one flank of the fish. 
Intramuscular Injections of GFP Plasmid and Electroporation 
We have  used  another  group  of  fish  where  inter  muscular  injection  was  given  and  after  that 
electroporation of DNA was performed. In this zebrafish group, we have performed electroporation of the 
muscle with a two-needle electrode to set at a voltage of 100 V. 
Expression of GFP in Zebrafish 
To observe  the  GFP expression after  two-three  days, anesthesia  provided  with  MS-222 and  the 
zebrafish were placed on petri-dish and were examined under blue light (490 nm) using an  Olympus 
fluorescent microscope, and photomicrographs were taken with a Olympus camera (C5050). 
RESULTS AND DISCUSSION
Expression of GFP in Only Injection Group
Luciferase expression was noted in anesthetized zebrafish at different days after plasmid injection by 
using a fluorescent microscope (Fig. 2A). The levels of luciferase gene expression were achieved after 24 
hours after injection which was stable for more than two weeks (Fig. 2C). We have documented 2-4 sports 
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in muscle in different fish after  plasmid administration. The expression was very strong in the site of 
injection in compare to electroporation group and the expression was very stable from the very beginning. 
Expression of GFP in Electroporation Group
In electroporation group, level of plasmid expression was more compared to injection group which 
declines within 3-4 days and then expression was stable (Fig.3A).  But, electroporation results  muscle 
injury. Recovery was noted which was very slow. Others workers has reported about muscle injury after 
electroporation in zebrafish model or in other animal model [5,19] . The expression was less strong in the 
site of injection in compare to first  group and the levels of luciferase gene expression was stable after 
more than two weeks same as above group (Fig. 3C).
Injection of plasmid with target DNA (in our case target gene was GFP gene) into the fish muscle was 
sufficient for expression of transgene into muscle cells that has also shown by some other workers [22, 
23]. To improve the effectiveness of transgene expression more, we have attempted electroporation after 
muscle injection of plasmid. Transfection efficiency is interconnected with electroporation parameters like 
number  of  pulses,  pulse duration and voltage strength.  As the  biochemical  and  physical  character  of 
tissues different, so, electroporation parameters are known to be different for each tissue. Each of these 
parameters is required to be optimized for each tissue [24].
The GFP gene expression suggests that there is a major influence of these parameters on cell entry of 
plasmid like number of pulses and voltage applied. At 10 µg of plasmid DNA per fish, we have noted 
major increase in GFP gene expression. (Fig. 1C). Below 10 µg of plasmid DNA, we could not detect 
luciferase activity. A previous report  on muscle injection of plasmid without electroporation recorded 
maximum expression at 5 µg of DNA into adult zebrafish [22].
Our studies demonstrate that plasmid incorporation offers several advantages over standard plasmid-
mediated gene therapy in which gene expression is mediated by extrachromosomal plasmids. High levels 
of  gene  expression  were  observed  in  muscles  in  the  place  of  plasmid  integration,  and  the  level  was 
considerably higher. We observed decline the number of spots (transgene expression )  in fish body in 
some fish which is due to loss of plasmid after injection. To get a stable and more expression, further work 
is necessary to address this issue.
In the near future, technologies to boost plasmid-mediated gene delivery by injection are likely to be 
at  the  front  position  as  nonviral  gene  therapy  approach.  It  is  apparent  from  human  clinical  trials 
concerning retroviral vectors that integration of exogenous elements into the human genome carries real 
risks [25]. For skeletal muscle and cardiac muscle gene therapy, the technology of ‘injection method’ for 
plasmid delivery is vital. It will be vital to identify the integration sites that would be considered for use in 
humans. For the gene therapy strategy where integration is probable, remains a safety concern. However, 
the results presented here demonstrate that the possibility of enhancing plasmid-mediated gene therapy is 
very promising and that needs further study.
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Figure 1.
 Schematic representation of  construction and composition of plasmid, pQE30GFP, which was 
used  for  injection  into  zebrafish  mussel.  (A)  For  production  of  pQE30GFP, we  have  inserted  GFP 
expression cassette into pQE30. GFP expression cassette was isolated from pEGFPC2 digested by Hind III 
and  KpnI
.  
(B)  Electrophoresis  of
 
plasmid  pQE30GFP treated  with  or  without  restriction  enzyme.  M: 
Molecular marker ; Lane 1: pQE30-EGFP; Lane 2：pQE30-EGFP treat with  HindIII; Lane 3:pQE30-
EGFP treat with Hind III  and Nde I
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Figure 2.
 GFP expression into muscle after  injection in zebrafish.  (A) An image taken at  the site of 
injection. (B) An image represents GFP expression other site of the body. (C) The number of sport for 
luciferase gene expression in respect to days (present data is from two fish).
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Figure 3.
 GFP expression  into  electroporation  group in  zebrafish.  (A) an  image taken at  the  site  of 
injection. (B) An image represents GFP expression other site of the body; (C) The number of sport for 
luciferase gene expression in respect to days (present data is from two fish; in one fish fluorescence sports 
are countable, but in case of other fish, sports are every much scattered which can not be countable ).
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